InsidersSo now that we are past the quarter Ly earnings, there is a window for insiders to purchase shares. To me this window will be the single biggest "tell" for oncology and what the future holds. If we see buying from key executives and board members, then I am inclined to believe their story and strategy has merit. If there is nothing or paltry sums bought then I am not going to give credibility to any word of it. PL has fallen out of my good books, but a big buy would restore confidence. As for Dubic, just quit already if you aren't willing to put some more skin in the game.